HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Among Firms Gaining Formula Import Approvals As Flood Closes Its Michigan Plant

As Perrigo Gains Market Share, CEO Expects Shortage To Continue Through 2022

Executive Summary

Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.  

You may also be interested in...

Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow

“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.

Recalls Have US FDA Looking At Nutritional Beverage Firms’ Microbial Contamination Controls

Lyons Magnus recalling 53 nutritional and other beverage products due to potential for microbial contamination, including same type linked to infant formula recall. FDA says reports of potential or confirmed unsafe bacterial levels led it to review its inspection records and industry's practices for preventing contaminations.

Abbott Hoists Forecast Sails Higher Despite Infant Formula, Inflation, Exchange Headwinds

Although sales of infant formula and other pediatric nutritionals were down more than 20% in US and more than 13% worldwide during Q2 on an organic measure – excluding a currency exchange impact – Abbott reports 14.3% overall sales growth to $11.3bn.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts